Kromek : Fundraising completed through convertible bond issue – | Region & Cash

August 05, 2022

Kromek Group plc

(“Kromek” or the “Company” or the “Group”)

Fundraising of £1.7m

Kromek Group plc, a leading developer of radiation and biodetection technology solutions for the Advanced Imaging and CBRN Detection segments, is pleased to announce that it has raised £1.7 million (the “Fundraising”) through the issuance of a convertible debentures (“Debentures”) to existing and new investors in the Company. Proceeds from the fundraising will be used to provide additional working capital to minimize potential supply chain disruptions in the delivery of contracts throughout the year.

The promissory notes have a term of 18 months (with the Company having the option to extend the majority of the promissory notes by three months), are senior and unsecured. The Loan Notes are convertible, at the option of investors, into common shares in the Company (“Common Shares”) at 15p per Common Share, representing a premium of 30% over the mid-point of the Company’s share price as at close of business 04 August 2022. The Notes are issued with a coupon of 8% per annum and have a conversion date of January 31, 2024.

Loan bondholders have the right to elect to be redeemed in whole or in part in common shares at the lower of the median closing price on the redemption date and 15p per share.

Based on a fundraising of £1.7 million, if converted at 15 pence per share, the Notes would represent approximately 11.3 million common shares, representing 2.6% of the Company’s currently issued share capital.

For more information please contact:

Kromek Group plc

Arnab Basu, CEO

+44 (0)1740 626 060

Paul Farquhar, Chief Financial Officer

finnCap Ltd (Nominated Advisor and Broker)

Geoff Nash/Seamus Fricker/George Dollemore – Corporate Finance

+44 (0)20 7220 0500

Tim Redfern/Charlotte Sutcliffe—ECM

Luther Pendragon (financial PR)

Harry Chathli/Claire Norbury

+44 (0)20 7618 9100

About Kromek Group plc

Kromek Group plc is a leading developer of radiation detection and biodetection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing facilities in the UK and US and realizes the vision of improving the quality of life through innovative detection technology solutions.

The Advanced Imaging segment includes the medical (including CT and SPECT), security and industrial markets. Kromek supplies its OEM customers with detector components based on its core

Cadmium Zinc Telluride (CZT) platform to enable better detection of diseases such as cancer and Alzheimer’s, contamination in industrial manufacturing and explosives in aviation.

In the area of ​​CBRN detection, the group provides nuclear radiation detection solutions for the global home defense and security market. Kromek’s compact, portable, high-performance radiation detectors, based on advanced scintillation technology, are primarily used to protect critical infrastructure and urban environments from the “dirty bomb” threat.

The group also develops biosecurity solutions in the CBRN detection segment. These consist of fully automated and autonomous systems for the detection of a variety of airborne pathogens.

Kromek is listed on the AIM, a market of the London Stock Exchange under the trading symbol ‘KMK’.

For more information, see

The information communicated in this announcement contains insider information within the meaning of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.


Kromek Group plc published this content on August 05, 2022 and is solely responsible for the information contained therein. Distributed by the public, unedited and unmodified, on 05 Aug 2022 13:55:13 UTC.

Public now 2022

All news about KROMEK GROUP PLC

Sale 2022 12.1 million
14.7 million
14.7 million
Net Income 2022 -4.37 million
-5.30 million
-5.30 million
Net Debt 2022 0.87 million
1.05 million
1.05 million
P/E 2022 -11.1x
Yield 2022
capitalization 49.7 million
60.3 million
60.3 million
EV / Sale 2022 4.18x
EV / Sale 2023 2.98x
number of employees 154
free float 54.1%

Duration :

Period :

Kromek Group plc Technical Analysis Chart |  MarketScreener

Trends in KROMEK GROUP PLC technical analysis

Short term medium term long term
tendencies bullish Neutral Neutral

Development of the income statement

To sell


Medium consensus TO BUY
Number of Analysts 1
Last closing price 11.50GB
Average target price 34.33GB
Spread / Average Target 199%

Leave a Comment